Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma

E. Franceschi, G. Cavallo, L. Scopece, A. Paioli, A. Pession, E. Magrini, R. Conforti, E. Palmerini, S. Bartolini, S. Rimondini, R. Degli Esposti, L. Crinò

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

We present the results of a phase II trial of carboplatin and etoposide (CE) combination as first-line chemotherapy in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) after surgery and radiotherapy. We assess the activity and the tolerability of this combination. 30 patients with GBM (25) and AA (5) were treated with VP-16 (etoposide) 120 mg m-2 and CBCDA (carboplatin) 100 mg m-2 for 3 days every 4 weeks. Moreover, we performed a retrospective analysis of topoisomerase IIα gene status using chromogenic in situ hybridisation. The median age was 54 years (21-73 years); Eastern Cooperative Oncology Group performance score was 0-1 in 25 patients and 2 in five patients. All patients had been previously treated with surgical resection (21 radical resections) followed by radiation therapy (40-60 Gy). We observed six (20%) complete responses, three (10%) partial responses and 12 (40%) stable diseases, with a response rate of 30%. The median time to progression was 4 months, while progression-free survival at 6 months was 33.3%. The median survival time was 10 months. Neutropenia occurred in 9 patients: four patients had grade 4, two patients grade 3 and three patients grade 2. In the conclusion of this clinical trial, the CE combination has shown activity in recurrent GBM and AA, with a good toxicity profile. Alterations in the copy number of topoisomerase IIα gene seem to be a rare event and in our series do not influence response to the CE combination.

Original languageEnglish
Pages (from-to)1038-1044
Number of pages7
JournalBritish Journal of Cancer
Volume91
Issue number6
DOIs
Publication statusPublished - Sep 13 2004

Fingerprint

Carboplatin
Etoposide
Glioma
Astrocytoma
Glioblastoma
Type II DNA Topoisomerase
Radiotherapy
Neutropenia
Genes
Disease-Free Survival
In Situ Hybridization
Clinical Trials
Drug Therapy
Survival

Keywords

  • Carboplatin
  • Chemotherapy
  • Etoposide
  • High-grade gliomas
  • Topoisomerase IIα

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Franceschi, E., Cavallo, G., Scopece, L., Paioli, A., Pession, A., Magrini, E., ... Crinò, L. (2004). Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. British Journal of Cancer, 91(6), 1038-1044. https://doi.org/10.1038/sj.bjc.6602105

Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. / Franceschi, E.; Cavallo, G.; Scopece, L.; Paioli, A.; Pession, A.; Magrini, E.; Conforti, R.; Palmerini, E.; Bartolini, S.; Rimondini, S.; Degli Esposti, R.; Crinò, L.

In: British Journal of Cancer, Vol. 91, No. 6, 13.09.2004, p. 1038-1044.

Research output: Contribution to journalArticle

Franceschi, E, Cavallo, G, Scopece, L, Paioli, A, Pession, A, Magrini, E, Conforti, R, Palmerini, E, Bartolini, S, Rimondini, S, Degli Esposti, R & Crinò, L 2004, 'Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma', British Journal of Cancer, vol. 91, no. 6, pp. 1038-1044. https://doi.org/10.1038/sj.bjc.6602105
Franceschi E, Cavallo G, Scopece L, Paioli A, Pession A, Magrini E et al. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. British Journal of Cancer. 2004 Sep 13;91(6):1038-1044. https://doi.org/10.1038/sj.bjc.6602105
Franceschi, E. ; Cavallo, G. ; Scopece, L. ; Paioli, A. ; Pession, A. ; Magrini, E. ; Conforti, R. ; Palmerini, E. ; Bartolini, S. ; Rimondini, S. ; Degli Esposti, R. ; Crinò, L. / Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. In: British Journal of Cancer. 2004 ; Vol. 91, No. 6. pp. 1038-1044.
@article{b2be3a16f21949909067d0f02bc2b6dc,
title = "Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma",
abstract = "We present the results of a phase II trial of carboplatin and etoposide (CE) combination as first-line chemotherapy in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) after surgery and radiotherapy. We assess the activity and the tolerability of this combination. 30 patients with GBM (25) and AA (5) were treated with VP-16 (etoposide) 120 mg m-2 and CBCDA (carboplatin) 100 mg m-2 for 3 days every 4 weeks. Moreover, we performed a retrospective analysis of topoisomerase IIα gene status using chromogenic in situ hybridisation. The median age was 54 years (21-73 years); Eastern Cooperative Oncology Group performance score was 0-1 in 25 patients and 2 in five patients. All patients had been previously treated with surgical resection (21 radical resections) followed by radiation therapy (40-60 Gy). We observed six (20{\%}) complete responses, three (10{\%}) partial responses and 12 (40{\%}) stable diseases, with a response rate of 30{\%}. The median time to progression was 4 months, while progression-free survival at 6 months was 33.3{\%}. The median survival time was 10 months. Neutropenia occurred in 9 patients: four patients had grade 4, two patients grade 3 and three patients grade 2. In the conclusion of this clinical trial, the CE combination has shown activity in recurrent GBM and AA, with a good toxicity profile. Alterations in the copy number of topoisomerase IIα gene seem to be a rare event and in our series do not influence response to the CE combination.",
keywords = "Carboplatin, Chemotherapy, Etoposide, High-grade gliomas, Topoisomerase IIα",
author = "E. Franceschi and G. Cavallo and L. Scopece and A. Paioli and A. Pession and E. Magrini and R. Conforti and E. Palmerini and S. Bartolini and S. Rimondini and {Degli Esposti}, R. and L. Crin{\`o}",
year = "2004",
month = "9",
day = "13",
doi = "10.1038/sj.bjc.6602105",
language = "English",
volume = "91",
pages = "1038--1044",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma

AU - Franceschi, E.

AU - Cavallo, G.

AU - Scopece, L.

AU - Paioli, A.

AU - Pession, A.

AU - Magrini, E.

AU - Conforti, R.

AU - Palmerini, E.

AU - Bartolini, S.

AU - Rimondini, S.

AU - Degli Esposti, R.

AU - Crinò, L.

PY - 2004/9/13

Y1 - 2004/9/13

N2 - We present the results of a phase II trial of carboplatin and etoposide (CE) combination as first-line chemotherapy in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) after surgery and radiotherapy. We assess the activity and the tolerability of this combination. 30 patients with GBM (25) and AA (5) were treated with VP-16 (etoposide) 120 mg m-2 and CBCDA (carboplatin) 100 mg m-2 for 3 days every 4 weeks. Moreover, we performed a retrospective analysis of topoisomerase IIα gene status using chromogenic in situ hybridisation. The median age was 54 years (21-73 years); Eastern Cooperative Oncology Group performance score was 0-1 in 25 patients and 2 in five patients. All patients had been previously treated with surgical resection (21 radical resections) followed by radiation therapy (40-60 Gy). We observed six (20%) complete responses, three (10%) partial responses and 12 (40%) stable diseases, with a response rate of 30%. The median time to progression was 4 months, while progression-free survival at 6 months was 33.3%. The median survival time was 10 months. Neutropenia occurred in 9 patients: four patients had grade 4, two patients grade 3 and three patients grade 2. In the conclusion of this clinical trial, the CE combination has shown activity in recurrent GBM and AA, with a good toxicity profile. Alterations in the copy number of topoisomerase IIα gene seem to be a rare event and in our series do not influence response to the CE combination.

AB - We present the results of a phase II trial of carboplatin and etoposide (CE) combination as first-line chemotherapy in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) after surgery and radiotherapy. We assess the activity and the tolerability of this combination. 30 patients with GBM (25) and AA (5) were treated with VP-16 (etoposide) 120 mg m-2 and CBCDA (carboplatin) 100 mg m-2 for 3 days every 4 weeks. Moreover, we performed a retrospective analysis of topoisomerase IIα gene status using chromogenic in situ hybridisation. The median age was 54 years (21-73 years); Eastern Cooperative Oncology Group performance score was 0-1 in 25 patients and 2 in five patients. All patients had been previously treated with surgical resection (21 radical resections) followed by radiation therapy (40-60 Gy). We observed six (20%) complete responses, three (10%) partial responses and 12 (40%) stable diseases, with a response rate of 30%. The median time to progression was 4 months, while progression-free survival at 6 months was 33.3%. The median survival time was 10 months. Neutropenia occurred in 9 patients: four patients had grade 4, two patients grade 3 and three patients grade 2. In the conclusion of this clinical trial, the CE combination has shown activity in recurrent GBM and AA, with a good toxicity profile. Alterations in the copy number of topoisomerase IIα gene seem to be a rare event and in our series do not influence response to the CE combination.

KW - Carboplatin

KW - Chemotherapy

KW - Etoposide

KW - High-grade gliomas

KW - Topoisomerase IIα

UR - http://www.scopus.com/inward/record.url?scp=5044222269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5044222269&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602105

DO - 10.1038/sj.bjc.6602105

M3 - Article

C2 - 15305187

AN - SCOPUS:5044222269

VL - 91

SP - 1038

EP - 1044

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -